Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting

Reuters

10/08

Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for <a href="https://laohu8.com/S/VP..UK">VP</a>-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting

Verrica Pharmaceuticals Inc. has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma $(BCC)$, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573936569"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573936569\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573936569?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573936569","market":"us","top_or_hot":-1,"title":"Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRCA\">Verrica Pharmaceuticals Inc.</a> has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a>. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-08 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRCA\">Verrica Pharmaceuticals Inc.</a> has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a>. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL4K3frW:1","article_id":"2573936569","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573936569","pubTimestamp":1759867517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting. Verrica Pharmaceuticals Inc. has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma , will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer . The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Verrica Pharmaceuticals在SITC 2025年年会上宣布VP-315治疗基底细胞癌的积极2期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9,"NDAQ":0.9},"content_text":"Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n    \n\nVerrica Pharmaceuticals Inc. has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma $(BCC)$, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}